Moderna will provide about 100 million doses, with the price coming to around $30.50 per person for a two dose regimen. The company’s vaccine candidate, mRNA-1273, is one of the few that have already advanced to the final stage of testing and is on track to be completed in September, the company said this month. The deal confirms that Moderna’s experimental vaccine is one of the leading contenders, said BMO analyst George Farmer, who has an “outperform” rating on the stock.
from Yahoo Finance https://ift.tt/3amPrAP
Leave a Reply